Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague
- PMID: 16377037
- DOI: 10.1016/j.vaccine.2005.11.047
Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague
Abstract
Mice were vaccinated with a recombinant fusion protein, rF1-V, by an intramuscular prime followed by an intranasal boost, to evaluate protection against pneumonic plague. Forty-two days after the intranasal boost, the mice were challenged by aerosol exposure to Yersinia pestis. Survival after exposure depended upon the dose of rF1-V given i.n. with > or = 80% survival in the highest dose groups. Pulmonary and serum antibody titers to V were the best predictors of outcome. For vaccinated mice that succumbed to the infection, death was delayed by 1-2 days compared to sham-inoculated controls. Weight loss early after exposure correlated with outcome. Pathology studies indicated a severe, necrotizing bronchopneumonia in vaccinated mice that succumbed to the infection, compatible with a prolonged disease course, while the lungs of sham-inoculated mice had only mild pneumonia, which is compatible with a more rapid disease course. Immunity in the respiratory tract appears to be critical for protection against primary pneumonia caused by Y. pestis.
Similar articles
-
Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.Vaccine. 2016 Nov 11;34(47):5768-5776. doi: 10.1016/j.vaccine.2016.09.063. Epub 2016 Oct 13. Vaccine. 2016. PMID: 27745954 Free PMC article.
-
Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.Vaccine. 2006 Mar 6;24(10):1625-32. doi: 10.1016/j.vaccine.2005.09.052. Epub 2005 Oct 7. Vaccine. 2006. PMID: 16243411
-
CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.Vaccine. 2009 Apr 6;27(16):2220-9. doi: 10.1016/j.vaccine.2009.02.016. Epub 2009 Feb 13. Vaccine. 2009. PMID: 19428836
-
Prospects for new plague vaccines.Expert Rev Vaccines. 2009 Dec;8(12):1721-38. doi: 10.1586/erv.09.129. Expert Rev Vaccines. 2009. PMID: 19943765 Review.
-
Plague.Vaccine. 2009 Nov 5;27 Suppl 4:D56-60. doi: 10.1016/j.vaccine.2009.07.068. Vaccine. 2009. PMID: 19837288 Review.
Cited by
-
Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor.Vaccine. 2012 Oct 5;30(45):6359-67. doi: 10.1016/j.vaccine.2012.08.051. Epub 2012 Sep 1. Vaccine. 2012. PMID: 22947140 Free PMC article.
-
Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model.Front Immunol. 2019 Aug 2;10:1830. doi: 10.3389/fimmu.2019.01830. eCollection 2019. Front Immunol. 2019. PMID: 31428104 Free PMC article.
-
Protection against pneumonic plague following oral immunization with a non-replicating vaccine.Vaccine. 2010 Aug 16;28(36):5924-9. doi: 10.1016/j.vaccine.2010.06.020. Epub 2010 Jun 19. Vaccine. 2010. PMID: 20600517 Free PMC article.
-
Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.Acta Biomater. 2019 Dec;100:326-337. doi: 10.1016/j.actbio.2019.10.016. Epub 2019 Oct 11. Acta Biomater. 2019. PMID: 31610342 Free PMC article.
-
Assessment of the risk of infectious aerosols leaking to the environment from BSL-3 laboratory HEPA air filtration systems using model bacterial aerosols.Particuology. 2014 Apr;13:82-87. doi: 10.1016/j.partic.2012.11.009. Epub 2013 Jun 15. Particuology. 2014. PMID: 38620193 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical